EPAC1 Pharmacological Inhibition with AM-001 Prevents SARS-CoV-2 and Influenza A Virus Replication in Cells
Viruses · 2023
DOI: 10.3390/v15020319 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Charlotte Foret-Lucas und 10 weiteren Autor:innen. Beteiligte Einrichtung: Ecole Nationale Vétérinaire de Toulouse, Université de Toulouse, ENVT, INRAE, IHAP, UMR 1225, 31300 Toulouse, France. Hauptthemen laut MEDLINE: COVID-19, Influenza A virus, Influenza, Human. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institut National de la Santé et de la Recherche Médicale (Inserm), Fondation pour la Recherche Médicale (Programme « équipe FRM 2021 »), Inserm Transfert (COP…, Institut national de recherche pour l’agriculture, l’alimentation et l’environnement (INRAE) and the French Ministère de l’Agriculture.
Abstract (Originalsprache)
The exceptional impact of the COVID-19 pandemic has stimulated an intense search for antiviral molecules. Host-targeted antiviral molecules have the potential of presenting broad-spectrum antiviral activity and are also considered as less likely to select for resistant viruses. In this study, we investigated the antiviral activity exerted by AM-001, a specific pharmacological inhibitor of EPAC1, a host exchange protein directly activated by cyclic AMP (cAMP). The cAMP-sensitive protein, EPAC1 regulates various physiological and pathological processes but its role in SARS-CoV-2 and influenza A virus infection has not yet been studied. Here, we provide evidence that the EPAC1 specific inhibitor AM-001 exerts potent antiviral activity against SARS-CoV-2 in the human lung Calu-3 cell line and the African green monkey Vero cell line. We observed a concentration-dependent inhibition of SARS-CoV-2 infectious viral particles and viral RNA release in the supernatants of AM-001 treated cells that was not associated with a significant impact on cellular viability. Furthermore, we identified AM-001 as an inhibitor of influenza A virus in Calu-3 cells. Altogether these results identify EPAC1 inhibition as a promising therapeutic target against viral infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ecole Nationale Vétérinaire de Toulouse, Université de Toulouse, ENVT, INRAE, IHAP, UMR 1225, 31300 Toulouse, France.
- Institute of Metabolic and Cardiovascular Diseases, INSERM, Université de Toulouse, UMR 1297-I2MC, 31432 Toulouse, France.
- Nancy Laboratory for Rabies and Wildlife, ANSES, Lyssavirus Unit, 54220 Malzéville, France.
- Nantes Université, CNRS, CEISAM, UMR 6230, 44000 Nantes, France.
ORCID-Profile: Charlotte Foret-Lucas, Pierre Bessière, Marine Wasniewski, Alexandre Servat, Arnaud Tessier, Frank Lezoualc'h
Förderung
- Institut National de la Santé et de la Recherche Médicale (Inserm), Fondation pour la Recherche Médicale (Programme « équipe FRM 2021 »), Inserm Transfert (COP…
- Institut national de recherche pour l’agriculture, l’alimentation et l’environnement (INRAE) and the French Ministère de l’Agriculture
Zitieren
APA
Foret-Lucas, C., Figueroa, T., Bertin, A., Bessière, P., Lucas, A., Bergonnier, D., Wasniewski, M., Servat, A., Tessier, A., Lezoualc'h, F., & Volmer, R. (2023). EPAC1 Pharmacological Inhibition with AM-001 Prevents SARS-CoV-2 and Influenza A Virus Replication in Cells. Viruses. https://doi.org/10.3390/v15020319
Vancouver
Foret-Lucas C, Figueroa T, Bertin A, Bessière P, Lucas A, Bergonnier D, et al. EPAC1 Pharmacological Inhibition with AM-001 Prevents SARS-CoV-2 and Influenza A Virus Replication in Cells. Viruses. 2023. doi:10.3390/v15020319
BibTeX
@article{ForetLucas2023,
author = {Foret-Lucas, Charlotte and Figueroa, Thomas and Bertin, Alexandre and Bessière, Pierre and Lucas, Alexandre and Bergonnier, Dorian and Wasniewski, Marine and Servat, Alexandre and Tessier, Arnaud and Lezoualc'h, Frank and Volmer, Romain},
title = {EPAC1 Pharmacological Inhibition with AM-001 Prevents SARS-CoV-2 and Influenza A Virus Replication in Cells},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15020319}
}
EUVIMED